Edition:
United States

Syndax Pharmaceuticals Inc (SNDX.OQ)

SNDX.OQ on NASDAQ Stock Exchange Global Select Market

8.93USD
23 May 2018
Change (% chg)

$0.24 (+2.76%)
Prev Close
$8.69
Open
$8.70
Day's High
$9.32
Day's Low
$8.70
Volume
87,497
Avg. Vol
106,603
52-wk High
$15.20
52-wk Low
$7.77

Chart for

About

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb... (more)

Overall

Beta: --
Market Cap(Mil.): $270.64
Shares Outstanding(Mil.): 22.22
Dividend: --
Yield (%): --

Financials

  SNDX.OQ Industry Sector
P/E (TTM): -- 30.95 32.75
EPS (TTM): -2.99 -- --
ROI: -42.86 14.84 14.38
ROE: -48.61 16.34 16.07

BRIEF-Syndax Announces Updated Results From Phase 2 Encore 601 Trial Of Entinostat In Combination With Keytruda®

* SYNDAX ANNOUNCES UPDATED RESULTS FROM PHASE 2 ENCORE 601 TRIAL OF ENTINOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB)

May 17 2018

BRIEF-Syndax Pharmaceuticals Reports Q1 Loss Per Share $0.79

* SYNDAX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE

May 08 2018

BRIEF-Syndax Pharmaceuticals Reports Q4 Loss Per Share $0.80

* SYNDAX PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE

Mar 05 2018

BRIEF-Syndax Pharmaceuticals Reports Qtrly Loss Per Share $0.80

* SYNDAX PHARMACEUTICALS - PHASE 2 ENCORE 601 PD-(L)1 REFRACTORY MELANOMA COHORT DATA AND MELANOMA REGISTRATION STRATEGY DISCLOSURE FORTHCOMING IN 2Q18

Mar 05 2018

BRIEF-Syndax Announces Immuno-Oncology Clinical Trial Collaboration With Astrazeneca

* SYNDAX ANNOUNCES IMMUNO-ONCOLOGY CLINICAL TRIAL COLLABORATION WITH ASTRAZENECA

Feb 01 2018

BRIEF-Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer

* SYNDAX PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ENTINOSTAT IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY IN BREAST CANCER

Jan 10 2018

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $35.97 +0.25
Novartis AG (NOVN.S) CHF76.16 -0.52
Eli Lilly And Co (LLY.N) $82.68 +0.46

Earnings vs. Estimates